AnatolyDritschiloMDFACR
Radiation Oncology • Washington, DCBreast Cancer, Head & Neck, Skin Cancer
Professor of Medicine, Georgetown University
Dr. Dritschilo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3800 Reservoir Rd Nw
Washington, DC 20007Phone+1 202-444-3320
Summary
- Dr. Dritschilo's current academic title is professor emeritus in Radiation Medicine at the Georgetown University School of Medicine and he serves as the CEO and Chairman of the Board of Directors of Shuttle Pharmaceuticals Holdings, Inc. a public biotech/pharma company (SHPH - Nasdaq).
Education & Training
Tufts Medical CenterResidency, Radiation Oncology, 1977 - 1977
Brigham and Women's Hospital/Joint Center for Radiation TherapyResidency, Radiation Oncology, 1974 - 1977
University of Cincinnati Medical Center Inc.Internship, Transitional Year, 1973 - 1974
Rutgers New Jersey Medical SchoolClass of 1973
Certifications & Licensure
DC State Medical License 1979 - 2024
MD State Medical License 1980 - 2024
VA State Medical License 1997 - 2018
American Board of Radiology Therapeutic Radiology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Top Doctors:Washington DC Area Castle Connolly, 2012
- Join now to see all
Clinical Trials
- Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies Start of enrollment: 2001 Mar 01
Publications & Presentations
PubMed
- 3 citationsCell therapy using ex vivo reprogrammed macrophages enhances antitumor immune responses in melanoma.Satish Kumar Reddy Noonepalle, Maria Gracia-Hernandez, Nima Aghdam, Michael Berrigan, Hawa Coulibaly
Journal of Experimental & Clinical Cancer Research. 2024-09-14 - Dual-targeting class I HDAC inhibitor and ATM activator, SP-1-303, preferentially inhibits estrogen receptor positive breast cancer cell growth.Mira Jung, Nicole Nicholas, Scott Grindrod, Anatoly Dritschilo
Plos One. 2024-01-01 - 4 citationsRadiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition.Satish Kumar R Noonepalle, Scott Grindrod, Nima Aghdam, Xintang Li, Maria Gracia-Hernandez
Molecular Cancer Therapeutics. 2023-12-01
Press Mentions
Shuttle Pharmaceuticals Hits Milestone in Patient Enrollment for Phase 2 Clinical TrialJanuary 22nd, 2025- Shuttle Pharmaceuticals Holdings, Inc. Finalizes Agreements for Phase 2 Clinical Trial Enrollment: Press Release AnalysisOctober 30th, 2024
- Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate UpdateMay 26th, 2023
- Join now to see all
Grant Support
- Mechanisms Of Cellular Responses To Ionizing RadiationNational Cancer Institute1997–2006
- Cancer Center Support GrantNational Cancer Institute2005
- Georgetown University AP4 Center PLANNational Cancer Institute2004
- Radiosensitization Of Pancreatic Cancers Through RAF-1National Cancer Institute2002
- Molecular Studies Of Radiation Resistant Tumor CellsNational Cancer Institute1997–2001
- ATM Gene In Breast Cancer--Prospective Clinical TrialNational Cancer Institute1997–2001
- Molecular Studies Of Radiation Resistant Tumor CellsNational Cancer Institute1987–2000
- Oligonucleotide Manipulation--Tumor Cell RadioresistanceNational Cancer Institute1994
- Radiation Resistance And Adp-Ribose MetabolismNational Cancer Institute1992–1994
- Molecular Basis Of Tumor Resistance To Ionize RadiationNational Cancer Institute1990–1992
- Characterization Of Differential Gene Expression In Resistant CellsNational Cancer Institute1990–1992
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
